merckincweb1

MSD’s investigational cytomegalovirus treatment shows significant promise in Phase 3 trial

pharmafile | February 27, 2017 | News story | Research and Development, Sales and Marketing MSD, cytomegalovirus, letermovir 

MSD has lifted the curtain on strong Phase 3 results in the development of its investigational antiviral drug letermovir, showing the treatment hit its primary endpoint of an improvement in clinically significant cytomegalovirus (CMV) infection following a bone marrow transplant.

A non-nucleoside CMV inhibitor, letermovir is currently in development as a preventative treatment of CVM infection in adult CMV-seropositive patients who have received an allogeneic hematopoietic stem cell transplant (HSCT).

The results showed that, of the 495 trial participants with baseline undetectable plasma CMV DNA, 37.5% of those treated with letermovir developed CMV by week 24, compared to 60.6% for placebo. In addition, the trial results indicate that the drug also led to lower all-cause mortality at 24 weeks, with 9.8% compared to 15.9% for placebo.

Advertisement

Based on the promising results, MSD plans to submit the drug to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for approval this year. It had previously been awarded fast track and orphan designations by the FDA.

Matt Fellows

Related Content

Lung xray image

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070

Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

Merck shares data from phase 3 trial of Keytruda for gastric cancers

Merck, known as MSD outside of the US and Canada, has announced data from the …

Merck to acquire Harpoon Therapeutics for approximately $680m

Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced …

The Gateway to Local Adoption Series

Latest content